The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Topical Imiquimod or Fluorouracil Therapy for Basal and Squamous Cell Carcinoma: A Systematic Review
Abstract
OBJECTIVES: To conduct a systematic review to determine clearance rates and adverse effects of topical imiquimod or fluorouracil therapy in the treatment of nonmelanoma skin cancers such as basal (BCC) and squamous cell carcinoma (SCC), and to develop recommendations for the use of topical imiquimod or fluorouracil to treat BCC and SCC. DATA SOURCES: MEDLINE, CANCERLIT, and Cochrane databases. STUDY SELECTION: Prospective, retrospective, and case studies in English containing a minimum of 4 subjects and a 6-month follow-up or posttreatment histologic evaluation. DATA EXTRACTION: We calculated the rate of clearance and adverse effects for BCC subtypes and invasive and in situ SCC treated with topical imiquimod or fluorouracil. DATA SYNTHESIS: Clearance rates varied by drug regimen, and most of the studies lacked long-term follow-up. Imiquimod use produced the following clearance rates: 43% to 100% for superficial BCC, 42% to 100% for nodular BCC, 56% to 63% for infiltrative BCC, 73% to 88% for SCC in situ, and 71% for invasive SCC. Fluorouracil use produced the following clearance rates: 90% for superficial BCC and 27% to 85% for SCC in situ. Up to 100% and 97% of patients applying imiquimod and fluorouracil, respectively, experienced at least 1 adverse event. Adverse event intensity ranged from mild to severe; erythema, pruritus, and pain were common. CONCLUSIONS: Evidence supports the use of topical imiquimod as monotherapy for superficial BCC and topical fluorouracil as monotherapy for superficial BCC and SCC in situ. Based on the available evidence, the strength of any recommendations for the use of these 2 agents in the primary treatment of these tumors is weak. We recommend that their use be limited to patients with small tumors in low-risk locations who will not or cannot undergo treatment with better-established therapies for which long-term clearance rates have been determined. Long-term clinical follow-up is essential for patients treated with topical imiquimod or fluorouracil. Limitations of therapy include high rates of adverse effects, lower clearance rates than other treatment modalities, dependence on patient adherence to treatment, and higher costs than other therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., & Akira, S. (2002) · Nature Immunology · doi:10.1038/ni758 · Cited by 2,522
Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
Guyatt, G., Gutterman, D., Baumann, M. H., Addrizzo-Harris, D., Hylek, E. M., Phillips, B., Raskob, G., Lewis, S. Z., & Schünemann, H. (2006) · Chest · doi:10.1378/chest.129.1.174 · Cited by 1,220
ROWE, D. E., CARROLL, R. J., & JR. DAY, C. L. (1989) · The Journal of Dermatologic Surgery and Oncology · doi:10.1111/j.1524-4725.1989.tb03166.x · Cited by 802
Ebell, M. H., Siwek, J., Weiss, B. D., Woolf, S. H., Susman, J., Ewigman, B., & Bowman, M. (2004) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.17.1.59 · Cited by 561
Geisse, J., Caro, I., Lindholm, J., Golitz, L., Stampone, P., & Owens, M. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.11.066 · Cited by 505
Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug
Miller, R. L., Gerster, J. F., Owens, M. L., Slade, H. B., & Tomai, M. A. (1999) · International Journal of Immunopharmacology · doi:10.1016/s0192-0561(98)00068-x · Cited by 417
Marks, R., Gebauer, K., Shumack, S., Amies, M., Bryden, J., Fox, T. L., & Owens, M. L. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.113689 · Cited by 333
Geisse, J. K., Rich, P., Pandya, A., Gross, K., Andres, K., Ginkel, A., & Owens, M. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.126215 · Cited by 281
Management of nonmelanoma skin cancer in 2007
Neville, J. A., Welch, E., & Leffell, D. J. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0883 · Cited by 278
Imiquimod 5% cream in the treatment of Bowen's disease
MacKenzie‐Wood, A. R., Kossard, S., de Launey, J. W., Wilkinson, B., & Owens, M. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.111335 · Cited by 264
Cited by
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
Liu, J., Fu, M., Wang, M., Wan, D., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01247-x · Cited by 715
Guidelines of care for the management of basal cell carcinoma
Bichakjian, C., Armstrong, A., Baum, C., Bordeaux, J. S., Brown, M., Busam, K. J., Eisen, D. B., Iyengar, V., Lober, C., Margolis, D. J., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.10.006 · Cited by 499
Self-citationThe Yin and Yang of Toll-like receptors in cancer
Pradere, J.-P., Dapito, D. H., & Schwabe, R. F. (2014) · Oncogene · doi:10.1038/onc.2013.302 · Cited by 331
Roozeboom, M. H., Aardoom, M. A., Nelemans, P. J., Thissen, M. R. T. M., Kelleners-Smeets, N. W. J., Kuijpers, D. I. M., & Mosterd, K. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.02.014 · Cited by 106
Reversing the aging stromal phenotype prevents carcinoma initiation
Lewis, D. A., Travers, J. B., Machado, C., Somani, A.-K., & Spandau, D. F. (2011) · Aging · doi:10.18632/aging.100318 · Cited by 66
Metadata
- Authors
- Love, W. E., Bernhard, J. D., & Bordeaux, J. S.
- Venue
- Archives of Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2009-12-01
- Volume
- 145
- Issue
- 12
- Pages
- 1431-8
- ISSN
- 0003-987X (ISSN-L)
- OpenAlex
- W2006936784
- Cited by
- 287
- References
- 29
- FWCI
- 11.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Topical Imiquimod or Fluorouracil Therapy for Basal and Squamous Cell Carcinoma: A Systematic Review. https://app.cochat.ai/papers/10.1001/archdermatol.2009.291
- The paper
- Love, W. E., Bernhard, J. D., & Bordeaux, J. S. (2009). Topical Imiquimod or Fluorouracil Therapy for Basal and Squamous Cell Carcinoma: A Systematic Review. Archives of Dermatology. https://doi.org/10.1001/archdermatol.2009.291
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.